Elevating Oncology Pharmacy Practice through Collaborative Practice Agreements
(Recorded HOPA Insights eSeries presented on 2/26/15)
Pharmacy collaborative practice agreements (CPA) are formal agreements where licensed providers refer patients to a pharmacist under a protocol that allows the pharmacist to perform specific care functions. Many have identified utilization of CPA’s as a method of utilizing the pharmacist as part of the interdisciplinary team to optimize drug management. This webinar will review the current state of CPA’s in the United States with a specific focus on oncology practices. Current best practices will be highlighted, as well as opportunities for future expansion.
- Discuss the current status of pharmacist collaborative practice agreements
- Identify opportunities for collaborative practice agreements in oncology settings
- Describe current collaborative practices utilized in oncology
John Valgus, PharmD BCOP
John Valgus is the Lead Pharmacist with the Hematology/Oncology Clinical Operating Group and a Clinical Pharmacist Practitioner with the Oncology Supportive Care Service at the University of North Carolina Medical Center. He is also an Assistant Clinical Professor at the UNC Eshelman School of Pharmacy, UNC School of Medicine, and the UNC School of Nursing. He is the Director of the Hematology/Oncology PGY2 Residency at UNC Hospitals. He is also a member of the UNC Institute for Pharmacogenomics and Individualized Therapy. Dr. Valgus is a Board Certified Oncology Pharmacist. His research and practice interests focus on supportive care in cancer patients and the implementation of personalized medicine.
Disclosure: The faculty and planners do not have anything to disclose.
This activity is intended for hematology/oncology pharmacists.
This activity has been approved for 1.25 contact hours (.125 CEUs) under the ACPE universal activity number 0465-0000-15-001-H01-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. A statement of credit will be issued only upon completion of the post-activity evaluation form and post-test, with a passing grade of 80% achieved. Individuals who attended the live broadcast of “Elevating Oncology Pharmacy Practice through Collaborative Practice Agreements” on February 26, 2015 and claimed live CE credit are ineligible to claim credit for completing this online activity.
View Webinar Free Here
To Claim Credit
If you would like to claim credit for the on demand webinar participants must:
(1) read the learning objectives and faculty disclosures
(2) view the recording
(3) purchase the online post-test by clicking here
(4) Follow the instructions on your email receipt to access the post-test;
(5) complete the online post-test and evaluation prior to printing out the certificate of completion.
Release Date: March 16, 2015
Expiration Date: Februrary 26, 2018
To receive credit, Purchase Now >
Disclosure of Conflicts of Interest
The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict
Planners and Managers
Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data.
Unlabeled/Unapproved Uses of Drugs
All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.